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The natural product CJ-15,801 is an inhibitor of
Staphylococcus aureus, but not other bacteria. Its
close structural resemblance to pantothenic acid,
the vitamin precursor of coenzyme A (CoA), and its
Michael acceptor moiety suggest that it irreversibly
inhibits an enzyme involved in CoA biosynthesis or
utilization. However, its mode of action and the basis
for its specificity have not been elucidated to date.
We demonstrate that CJ-15,801 is transformed by
the uniquely selectiveS. aureus pantothenate kinase,
the first CoA biosynthetic enzyme, into a substrate
for the next enzyme, phosphopantothenoylcysteine
synthetase, which is inhibited through formation of
a tight-binding structural mimic of its native reaction
intermediate. These findings reveal CJ-15,801 as
a vitamin biosynthetic pathway antimetabolite with
a mechanism similar to that of the sulfonamide anti-
biotics and highlight CoA biosynthesis as a viable
antimicrobial drug target.
INTRODUCTION
The antibiotic CJ-15,801 (1; Figure 1A) was discovered in 2001
by a Pfizer research team when it was isolated from fermenting
cultures of a Seimatosporium sp. fungus (Sugie et al., 2001).
Structural analysis showed the compound to resemble panto-
thenic acid (vitamin B5, 2; Figure 1B), the natural precursor of
the essential metabolic cofactor coenzyme A (CoA, 3) (Strauss,
2010), with the notable exception of a trans-substituted double
bond in the b-alanine moiety. This feature imparts an N-acyl
vinylogous carbamic acid functionality to 1, an uncommon motif
that is also present in the anticancer agent palytoxin and
lipopeptide antibiotics such as enamidonin (Han et al., 2004;
Nicolaou and Mathison, 2005). Subsequently, CJ-15,801 was
shown to inhibit the growth of drug-resistant strains of Staphylo-
coccus aureus (MRSA) with minimum inhibitory concentration
(MIC) values ranging between 6.25 and 50 mg/ml (30–230 mM).
Interestingly, other bacteria, including Escherichia coli, Haemo-Chemistry & Biology 19,philus influenzae, and several Streptococcus species, were not
inhibited. In a later study, Saliba and Kirk determined that
CJ-15,801 also inhibits the intraerythrocytic growth stage of
the malaria parasite Plasmodium falciparum with an IC50 value
of 39 mM, while leaving rat hepatoma tissue culture (HTC) cells
unaffected (Saliba and Kirk, 2005). Moreover, the malarial inhibi-
tion was reversed when the concentration of pantothenic acid in
the medium was increased. Taken together, these findings all
pointed to CJ-15,801 targeting CoA biosynthesis, or an enzyme
or process dependent on this cofactor (Spry et al., 2008, 2010).
However, such a proposal has not been confirmed experimen-
tally in any of the organisms sensitive to CJ-15,801, nor does it
provide a satisfactory explanation for this antibiotic’s peculiar
selectivity.
The presence of the N-acyl vinylogous carbamic acid
functionality in CJ-15,801, combined with a knowledge of the
chemical and biological reactivity of other inhibitors with similar
reactive moieties, suggests that 1most probably acts as an irre-
versible inhibitor of its biological target. Two mechanisms for
such inhibition can be proposed: first, the a,b-unsaturated
carbonyl moiety can act as a Michael-acceptor that would trap
an active site nucleophile (Figure 1C); such a mechanism of
action is seen in the structurally related dapdiamide family of
antibiotics (Hollenhorst et al., 2011; Kucharczyk et al., 1990)
and has also been exploited in the development of irreversible
inhibitors of CoA disulfide reductase (van der Westhuyzen and
Strauss, 2010). Second, if the carboxylate of CJ-15,801 were
functionalized in an enzymatic transformation with an appro-
priate leaving group, this may provide sufficient activation for
the formation of a reactive ketene intermediate that could simi-
larly act as an electrophilic trap (Figure 1D). Importantly, both
of these mechanisms would remain equally viable if the 40-OH
group of CJ-15,801 is phosphorylated or otherwise functional-
ized, suggesting it could be transformed by the CoA biosynthetic
enzymes into an inhibitory CoA analog with a target downstream
of the pathway. Such a mechanism of action has been demon-
strated for the pantothenamides, a class of pantothenic acid
analogs in which its carboxylate has been functionalized by ami-
dation (Clifton et al., 1970; van Wyk and Strauss, 2008). For
example, N-pentylpantothenamide (N5-Pan, 4), which acts as
a bacteriostatic agent in both E. coli and S. aureus (Choudhry
et al., 2003), is transformed by three of the five CoA biosynthetic559–571, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 559
Figure 1. Structures of the Antibiotic CJ-15,801 (1), Selected Coenzyme A Biosynthetic Intermediates, Antimetabolites, and Intermediate
Mimics
(A) Structure of the CJ-15,801 (1).
(B) Biosynthesis of CoA (3) from pantothenic acid (2). PanK, pantothenate kinase; PPCS, phosphopantothenoylcysteine synthetase; PPCDC, phosphopanto-
thenoylcysteine decarboxylase; PPAT, phosphopantetheine adenylyltransferase; DCPK, dephospho-coenzyme A kinase.
(C) Proposed mechanism for irreversible inhibition by CJ-15,801 acting as an electrophilic trap.
(D) Proposed mechanism for irreversible inhibition by CJ-15,801 after its transformation into a ketene intermediate.
(E) Biotransformation of the pantothenic acid analog N-pentylpantothenamide (4) to the CoA antimetabolite ethyldethia-CoA (5), which has the catalytically
essential thiol of the cofactor replaced by a propyl group. The antimetabolite subsequently serves as donor in the phosphopantetheinyl transferase (PPTase)-
catalyzed posttranslational modification of acyl and peptidyl carrier proteins (CPs), which results in similarly inactive crypto-CPs.
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Mode of Action of the Antibiotic CJ-15,801enzymes into ethyldethia-CoA (5), a CoA antimetabolite that
lacks the thiol required for the cofactor’s acyl carrier functions
(Figure 1E) (Strauss and Begley, 2002). This analog subsequently
serves as donor in the posttranslational modification of the
apo-acyl carrier protein (ACP), leading to the formation of cata-
lytically inactive crypto-ACP (Leonardi et al., 2005; Mercer and
Burkart, 2007; Zhang et al., 2004). The resulting loss of function
and subsequent impact on fatty acid metabolism is believed to
be the major cause for bacteriostasis, although a recent study
pointed to an impact on CoA biosynthesis as well (Thomas and
Cronan, 2010).
Interestingly, like CJ-15,801, the pantothenamides also exhibit
organism-based specificity. While the basis for this specificity
may partially reflect differences in the targeted organism’s cell560 Chemistry & Biology 19, 559–571, May 25, 2012 ª2012 Elsevierpermeability and/or the nature of potential drug efflux pumps,
the most important factor relates to the nature of the pantothe-
nate kinase (PanK) enzyme present in the cell. PanK catalyzes
the first step of CoA biosynthesis, namely the ATP-dependent
phosphorylation of pantothenic acid (2) to form 40-phosphopan-
tothenic acid (P-Pan, 6) (Figure 3A). This reaction is unique
because it is catalyzed by three distinct types of PanK, referred
to as type I, type II, and type III, respectively. These different
PanK types can be distinguished based on their sequence,
structure, the extent to which they experience feedback inhibi-
tion by CoA, and importantly, their ability to act on pantothena-
mides as alternative substrates (Brand and Strauss, 2005;
Hong et al., 2006; Strauss, 2010; Strauss et al., 2010; Yang
et al., 2008). Only type I and II PanKs (PanKI and PanKII)Ltd All rights reserved
Figure 2. Synthesis of CJ-15,801, Its Methyl Ester and Their Respec-
tive Phosphorylated Versions
The respective reaction conditions are as follows: (a) Allyl- or methylacetyl-
triphenylphosphonium bromide, Et3N, toluene, 90
C, 75% (Villa et al., 2007);
(b) BiCl3, H2O, CH3CN, room temperature, 5 hr, 75%; (c) Pd(PPh3)4, pyrollidine,
THF, 81%; (d) SaPanK, ATP, MgCl2, Tris-HCl (pH 7.5), 98% (for 12); 79%
(for 13).
See also Figure S3.
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Mode of Action of the Antibiotic CJ-15,801phosphorylate pantothenamides, thereby allowing the forma-
tion of CoA antimetabolites. Organisms like Pseudomonas
aeruginosa that have type III PanK (PanKIII) enzymes that exclude
these compounds from their active sites are therefore refractory
to the effects of N-pentylpantothenamide and similar analogs
(Balibar et al., 2011). This suggests that the basis for CJ-
15,801’s unique specificity for S. aureus and P. falciparum may
also be based on the type specificity of their PanKs, both of
which have been characterized as atypical type II enzymes
(Hong et al., 2006; Leonardi et al., 2005; Spry et al., 2010).
In this study, we set out to identify the target of CJ-15,801’s
antibiotic action in bacteria, to elucidate its mechanism of action,
and to establish the basis for its specificity. Our results reveal
that CJ-15,801 acts as an antimetabolite by using the first
enzyme of the CoA biosynthesis as gateway to the pathway,
after which it inhibits the second CoA biosynthetic enzyme,
phosphopantothenoylcysteine synthetase (PPCS). This mode
of action is reminiscent of the sulfonamide antibiotics, which
block folic acid biosynthesis using a similar strategy. However,
contrary to expectations, detailed analysis of the inhibition
mechanism failed to provide any evidence of irreversible inhibi-
tion. Instead, our results show that CJ-15,801 is transformed
into a tight-binding mimic of the PPCS enzyme’s natural reaction
intermediate, a mechanism also utilized by other known naturalChemistry & Biology 19,product inhibitors of adenylating enzymes, such as ascamycin
and mupirocin (May et al., 2005; Pope et al., 1998). Taken
together, these findings not only provide insight into the basis
of CJ-15,801’s antibiotic action, but also suggest a new and
potentially general strategy for the development of synthetase
inhibitors with in vivo efficacy.
RESULTS
Synthesis of CJ-15,801 and Its Esters
The synthesis of CJ-15,801 and its related analogs presents
several challenges, the first of which relates to the preparation
of the N-acyl vinylogous carbamic acid moiety. In fact, several
groups have used the synthesis of CJ-15,801 to showcase
new methodologies developed specifically for the preparation
of this functionality (Han et al., 2004; Lee et al., 2006; Nicolaou
and Mathison, 2005). However, we found these methods to be
unsuitable for this study as they are either optimized for small-
scale synthetic preparations, or led to the preferential formation
of the unwanted (Z)-double bond configuration. We therefore
utilized the more recent method of Villa et al., which installs the
required N-acyl vinylogous carbamic acid moiety mainly with
an (E)-configuration via Wittig-type chemistry, for preparation
of the protected esters 8 and 9 (Figure 2) (Villa et al., 2007). A
second challenge derives from the sensitivity of the N-vinyl
amide moiety to both acid and base, which severely restricts
the options for the protection and deprotection of the synthetic
intermediates. In this case, established protocols that make
use of neutral conditions were used to remove the acetal pro-
tecting groups from 8 and 9 to, respectively, obtain CJ-
15,801’s allyl (10) and methyl (11) esters, and to remove the allyl
ester from 10 to provide CJ-15,801 itself. The (Z)-configured
analog of CJ-15,801 (Z-1) was obtained by similar deprotection
of the minor constituent of the Wittig coupling reaction product
mixture.
Recently, an updated report of the Wittig-based synthesis of
CJ-15,801 appeared in which several other options for deprotec-
tion of its carboxyl group are also provided (Sewell et al., 2011).
A Bacterium’s Susceptibility to CJ-15,801 Correlates
with Its PanK Type
The original Pfizer discovery group found that in standard
susceptibility tests conducted using cation adjusted Mueller-
Hinton broth as growthmediumCJ-15,801 is uniquely and pecu-
liarly selective for S. aureus, with none of the other organisms
tested showing inhibition at 100 mg/ml (460 mM) (Sugie et al.,
2001). These resistant organisms included both Gram-positive
(Staphylococcus, Enterococcus, and Streptococcus spp.) and
Gram-negative (H. influenzae, Moraxella catarrhalis, and E. coli)
bacteria, indicating that cell envelope type alone does not deter-
mine selectivity. However, the panel of test organisms also
comprised bacteria expressing all three known pantothenate
kinase (PanK; Figure 3A) types: the enterococci, streptococci,
H. influenzae, and E. coli are known or predicted to have PanKI
enzymes, while M. catarrhalis is predicted to have a PanKIII
(Yang et al., 2006). Importantly, the staphylococci are the only
known bacteria to have an active PanKII, suggesting that the
presence of this PanK type is a prerequisite for inhibition by
CJ-15,801.559–571, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 561
Figure 3. Evaluation of PanK as a Potential Gate-
keeper to CJ-15,801’s Inhibitory Action
(A) The ATP-dependent phosphorylation of pantothenic
acid (2) catalyzed by PanK enzymes.
(B) HPLC analysis of the putative ATP-dependent phos-
phorylation of CJ-15,801 by SaPanK. The traces repre-
sent: I, a synthetically prepared standard of CJ-15,801 (1);
II, a reaction mixture containing CJ-15,801, ATP and
SaPanK that had been incubated for 1 min; III, the same
after 10 min of incubation; and IV, a synthetic P-CJ (13)
standard. The peak labeled with (d) represents ATP
and ADP.
See also Table S2.
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Mode of Action of the Antibiotic CJ-15,801To test this hypothesis, we repeated the CJ-15,801 suscepti-
bility tests against a panel of organisms representing all combi-
nations of cell envelope and PanK type. Since the original tests
were conducted in growth medium rich in pantothenic acid,
these experiments were conducted in 1% tryptone (that contains
essentially no pantothenic acid) instead to exclude any potential
antagonistic effects that the presence of the vitamin could have
on inhibition. The results show that the PanKII-containing
S. aureus (MRSA strain TCH1516) was the most sensitive to
the inhibitory effects of CJ-15,801, showing an MIC of 15 mM
(Table S1 available online). This value is 2-fold lower than the
lowestMIC reported in the previous susceptibility tests, suggest-
ing that pantothenate does affect inhibition similar to what was
seen in the experiments with malaria parasites (Saliba and
Kirk, 2005). Moreover, under these test conditions some of the
other organisms (most notably P. aeruginosa) also showed low
levels of inhibition (MIC 60 mM).
To determine which aspects of CJ-15,801’s structure are
required for inhibition, we evaluated the inhibitory activity of
the (Z)-configured analog (Z-1) and CJ-15,801’s methyl ester
(CJ-OMe, 11) against S. aureus. Neither compound showed
any inhibition, indicating that the configuration of the double
bond and the availability of the free carboxylate of CJ-15,801
are both important determinants for its mechanism of inhibition.
Only PanKII Enzymes Accept CJ-15,801 as Substrate
To confirm that the observed inhibition results can indeed be
correlated with PanK type and activity, we performed in vitro
activity analyses using purified PanK enzymes. Based on the
inhibition results, we first used the most likely candidate,
the PanKII enzyme from S. aureus (SaPanKII), to determine if
it converts CJ-15,801 to phospho-CJ,15,801 (P-CJ, 13)
when incubated with ATP. High-performance liquid chromatog-
raphy (HPLC) analysis of the reaction mixture confirmed
this to be the case, based on the time-dependent formation
of P-CJ (Figure 3B). Next, the activity of the PanKI from
E. coli (EcPanKI), SaPanKII, and the PanKIII from P. aeruginosa
(PaPanKIII) toward CJ-15,801 were fully characterized kineti-
cally. The resulting data indicate that EcPanKI and PaPanKIII
only show activity toward pantothenic acid and not CJ-15,801;562 Chemistry & Biology 19, 559–571, May 25, 2012 ª2012 Elsevier Ltd All rights resemoreover, neither enzyme was inhibited by
100 mM CJ-15,801 (Table S2). However,
SaPanKII shows little distinction between
CJ-15,801 and pantothenic acid, exhibitingspecificity constants (kcat/Km) of 13.8 ± 4.2 mM
1$s1 and
30.2 ± 8.7 mM1$s1 for the two compounds, respectively,
with the difference being mainly due to an elevated Km value.
The enzyme also acts on CJ-OMe, indicating that the lack of inhi-
bition seen for this analog is due to effects downstream of PanK.
Taken together, these results indicate that PanK acts as
a gatekeeper to the inhibitory effects of CJ-15,801 in S. aureus.
CJ-15,801’s Antistaphylococcal Activity Is Affected
by Pantothenic Acid and Pantetheine
The observation that S. aureus’s susceptibility to inhibition by
CJ-15,801 is apparently affected by pantothenic acid (2), as
well as the finding that SaPanKII accepts both the inhibitor and
the vitamin as substrates, led us to perform checkerboard
assays to quantify these effects (Figure 4A). The same
assay was also conducted with pantetheine (17), the precursor
to the CoA salvage pathway that bypasses the PPCS and phos-
phopantothenoylcysteine decarboxylase (PPCDC) enzymes
(Strauss, 2010; Strauss et al., 2010) (Figure 4B). The results
show that the presence of either compound reduces the potency
of CJ-15,801, most likely through competition with SaPanKII.
However, their interaction with the natural product is complex,
since increasing the concentration of either compound above
a certain level (7.5 mM for 2, and 15 mM for 17) leads to inhi-
bition being reestablished. While the basis for this observation
is currently unknown, the results confirm that the point of CJ-
15,801’s inhibitory action is a process dependent on pantothenic
acid (or pantetheine).
Pantothenamides Increase the Potency of CJ-15,801’s
Antistaphylococcal Activity
Previous studies have shown that treatment of S. aureus with
N5-Pan (and its analog, N-heptylpantothenamide, N7-Pan)
results in growth inhibition by formation of inactive carrier
proteins (Figure 1E) (Leonardi et al., 2005; Zhang et al., 2004).
To determine if the points of action of the pantothenamides
and CJ-15,801 overlap, a checkerboard assay with N5-Pan (4)
and CJ-15,801 was performed in 1% tryptonemedia (Figure 4C).
The results show that when combined, CJ-15,801 and N5-Pan
exhibited significantly reduced MICs of 3.75 mM and 1.0 mM,rved
Figure 4. Synergism in the Antibacterial Action of CJ-15,801 and N5-Pan
(A) Checkerboard assay of the growth inhibition of S. aureus by CJ-15,801 (1) when grown in the presence of pantothenic acid (2) in 1% tryptone shows that
increasing the amount of vitamin (up to a certain concentration) reverses the inhibition. MIC value for CJ-15,801 is 15 mM.
(B) As for (A), but with pantetheine (17) added instead of pantothenic acid.
(C) Checkerboard assay of the growth inhibition of S. aureus grown in 1% tryptone by CJ-15,801 (1) and N5-Pan (4) demonstrates the synergism between these
compounds (FICI < 0.5). MIC value for N5-Pan is 30 mM.
(D) As for (C), but determined in the presence of 100 mM pantothenic acid (2), demonstrating that the combination of CJ-15,801 and N5-Pan can overcome the
antagonism caused by an excess of the natural substrate of the CoA biosynthetic pathway, but at the expense of converting the synergism to an additive effect
(0.5 < FICI < 1.0).
See also Tables S1 and S3.
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Mode of Action of the Antibiotic CJ-15,801respectively, with a fractional inhibitory concentration index
(FICI) of 0.25, indicating synergism (Table S3). Importantly,
when the same assay was performed in the presence of
100 mM pantothenic acid, the inhibition was not as adversely
affected as in the case of the individual compounds (Figure 4D).
Instead, theMIC values were slightly elevated and the previously
observed synergism was converted to an additive inhibitory
effect (FICI 0.5–1.0) (Table S3). This finding suggests that CJ-
15,801 and N5-Pan does not have the same mode of action
and indicates that in combination these compounds can counter
the antagonism caused by pantothenic acid.
Synthesis of the 40-Phosphates of CJ-15,801
and Its Methyl Ester
The discovery that SaPanK phosphorylates both CJ-15,801 and
CJ-OMe (11) provided us with a convenient biocatalytic method
by which their 40-phosphorylated versions could be prepared.
P-CJ (13) and its methyl ester, 12 (P-CJ-OMe), were therefore
obtained by milligram-scale biotransformations using recombi-
nant SaPanK and ATP, followed by purification by either
preparative HPLC (for P-CJ) or solid-phase extraction (SPE)
(for P-CJ-OMe) (Figure 2).
PPCS Accepts P-CJ as Substrate and Is Then Inhibited
by It
With the knowledge that CJ-15,801 can be converted to P-CJ
within S. aureus, we set out to determine if PPCS, the next
enzyme in the pathway, is the target for the antibiotic’s inhibitory
action. PPCS catalyzes the condensation of P-Pan (6) with
L-cysteine to form 40-phosphopantothenoylcysteine (PPC, 15)
using a two-step acyl transfer mechanism common to most
synthetase (C-N ligase) enzymes, including all the amino
acid tRNA synthetases and the adenylation domains of the
modular nonribosomal peptide synthetases (NRPSs) (Figure 5A)Chemistry & Biology 19,(Schimmel et al., 1998; Sieber and Marahiel, 2005). While
all known PPCSs follow this general scheme, bacterial
enzymes are unique in that they use CTP instead of ATP as
nucleotide source for the activation reaction, and therefore
form 40-phosphopantothenoyl-CMP (P-Pan-CMP, 14) as inter-
mediate (Kupke, 2002, 2004; Manoj et al., 2003; Stanitzek
et al., 2004; Strauss, 2010; Strauss et al., 2001).
In most bacteria PPCS activity is located on one domain of the
bifunctional CoaBC protein (which also carries PPCDC activity),
although monofunctional PPCS enzymes do occur in certain
enterococci (such as Enterococcus faecalis [Yao et al., 2009])
and streptococci. Among all bacterial PPCS enzymes the
PPCS activity of E. coli’s bifunctional CoaBC protein is by far
the best studied: its mechanism has been established through
trapping and isolation of P-Pan-CMP (14), and the structure of
the N210D mutant with the trapped intermediate 14 bound in
the active site has been determined (Kupke, 2002, 2004; Stanit-
zek et al., 2004). Moreover, many of these studies were per-
formed using the separate PPCS domain (EcPPCS) expressed
and purified on its own, showing that the two activities of the
bifunctional CoaBC protein are independent. This conclusion is
also supported by kinetic isotope studies of the PPCDC activity
of E. coli’s CoaBC (Strauss and Begley, 2001). We therefore
decided to use the EcPPCS domain to perform the initial tests
on the interaction of PPCS and P-CJ.
To determine if P-CJ is accepted as an alternate substrate by
PPCS and forms the corresponding P-CJ-CMP intermediate 16
(Figure 5B), mixtures of P-CJ and CTP were incubated with
increasing concentrations of EcPPCS. A clear correlation
between the rate of pyrophosphate release and enzyme concen-
tration was evident in such reactions (Figure 5C). Moreover,
HPLC analysis of the reaction mixture containing the highest
EcPPCS concentration (24 mM) showed the formation of
a peak absent in native reaction mixtures, or in mixtures559–571, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 563
Figure 5. Evaluation of PPCS Activity with P-CJ (13) as Substrate
(A) The reaction catalyzed by PPCS, showing the two steps of its mechanism
and the P-Pan-CMP (14) reaction intermediate.
(B) The structure of P-CJ-CMP (16) resulting from the putative cytidylation of
P-CJ (13) by PPCS.
(C) The rate of pyrophosphate release from a reaction mixture containing P-CJ
(13), CTP, and EcPPCS correlates with enzyme concentration. Experiments
were run in duplicate; the shown data points are the average of duplicate
assays (error bars indicate the SD).
(D) HPLC analysis of a reaction mixture containing P-CJ (13), CTP, and
EcPPCS (24 mM) (trace I) show the formation of a new peak (indicated with an
asterisk) that represents P-CJ-CMP (16) based on LC-MS analysis. This peak
is not present when P-CJ is replaced with P-Pan (6) (trace II) or in native
reaction mixtures containing P-Pan, CTP and L-cysteine. Note that the
retention time of pure P-CJ is2.4min (see Figure 2B). The broad peak labeled
with (B) represents CTP and CMP.
See also Figure S1.
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564 Chemistry & Biology 19, 559–571, May 25, 2012 ª2012 Elseviercontaining P-Pan (6) instead of P-CJ, suggesting the formation of
P-CJ-CMP (Figure 5D). Note that P-Pan-CMP is usually not
observed under these conditions, as was previously reported
(Kupke, 2002, 2004). Liquid chromatography-tandem mass
spectrometry (LC-MS) analysis was subsequently conducted
on the same mixture. While the P-CJ-CMP-derived molecular
ion was not observed, the corresponding mass spectrum did
show mass peaks that are in agreement with the fragmentation
of P-CJ-CMP (Figure S1). The same experiment was subse-
quently repeated with the bifunctional CoaBC protein from
S. aureus (SaCoaBC). A similar result was obtained, although
the apparent rate of conversion of P-CJ into P-CJ-CMP was
significantly slower than for EcPPCS (Figure S1).
In combination, these results indicate that P-CJ is accepted as
an alternate substrate by PPCS, which cytidylylates its carbox-
ylate to form P-CJ-CMP.
PPCS Transform P-CJ into P-CJ-CMP, which Inhibits
Its Activity
Subsequent activity analysis of PPCS in the presence of P-CJ,
CTP, and L-cysteine failed to show catalytic turnover. Moreover,
when P-CJ was added to PPCS reaction mixtures containing the
enzyme’s native P-Pan substrate, the rate of the reaction was
reduced compared to mixtures without it, suggesting inhibition
by P-CJ. To confirm that such inhibition is dependent on the
reaction catalyzed by PPCS, an inhibition screen was performed
in which CJ-15,801, CJ-OMe, P-CJ, or P-CJ-OMe was added to
native PPCS reaction mixtures at a concentration of 100 mM. The
results showed that among these compounds, only P-CJ
inhibited EcPPCS (data not shown). The lack of inhibition by
P-CJ-OMe indicated that the free carboxylate group is required
for inhibition, while the inability of CJ-15,801 to affect enzyme
activity highlights the necessity of the phosphate group for
binding. Taken together with the results described above, these
findings reveal PPCS as CJ-15,801’s target of inhibitory action,
which is achieved through formation of P-CJ-CMP 16 as an
apparent dead-end inhibitor.
Kinetic Characterization Reveals P-CJ-CMP
as a Tight-Binding Inhibitor of PPCS
Inhibition by P-CJ-CMP could potentially occur by either of the
proposed irreversible inhibition mechanisms (Figures 1C and
1D), or by a completely unrelated mechanism. To elucidate the
actual mechanism of inhibition, detailed kinetic analyses were
performed. First, dose-response curves were used to evaluate
the inhibition of the cytidyl-transfer reaction catalyzed by
EcPPCS. The resulting IC50 value of 2.66 ± 0.16 mM, determined
using saturating concentrations of CTP and 100 mM P-Pan (note
that EcPPCS experiences substrate inhibition, see Figure S2),
was less than 10-fold the concentration of enzyme used in these
assays (240 nM). This indicated that P-CJ-CMP acts as either
a tight-binding or irreversible inhibitor of EcPPCS (Copeland,
2000). The inhibition of EcPPCS was next studied by the prog-
ress curve method. The resulting curves increased in a linear
fashion, showing a decreased rate at increased concentrations
of P-CJ (Figure 6A). Surprisingly, this indicated that the inhibition
was tight binding and not irreversible (which would have led
to the steady-state rates approaching zero) as predicted
(Copeland, 2005). This finding was confirmed by showing thatLtd All rights reserved
Figure 6. Kinetic Characterization of the CJ-15,801-Based Inhibition of PPCS
(A) Progress curves analysis for the inhibition of EcPPCS in the presence of increasing concentrations of P-CJ (13), indicated in nM next to each curve.
(B) Plot of the fractional activity (initial velocity vi relative to the inhibited velocity v0), as determined from the progress curves in (A), against inhibitor concentration.
The indicated Ki value is determined by fitting the data to the Morrison and Cheng-Prusoff equation.
(C) Determination of the inhibition modality of EcPPCS by P-CJ (13) by calculation of the IC50 values in the presence of increasing concentrations of P-Pan (6) (d),
and CTP (B).
(D) Progress curves analysis for the inhibition of SaCoaBC in the presence of increasing concentrations of P-CJ (13), indicated in nM next to each curve.
(E) Plot of the first order rate of inactivation constants (kobs), as determined from the data presented in (D), against inhibitor concentration. The indicated Ki value is
determined by fitting the data to the equation for a straight line.
(F) Plot of the fractional activity (steady-state velocity vs relative to the inhibited velocity v0), as determined from the progress curves in (D), against inhibitor
concentration. The indicated Ki value is determined by fitting the data to a Langmuir isotherm.
All progress curve analyses were performed in triplicate (error bars represent the SD).
See Supplemental Experimental Procedures for details on calculations, as well as Figure S2 for the determination of EcPPCS and SaCoaBC kinetic parameters.
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Mode of Action of the Antibiotic CJ-15,801removal of the inhibitor by gel filtration was sufficient to restore
the activity of a sample of EcPPCS that had been pretreated
with P-CJ and CTP.
The Ki
app (apparent inhibition constant) was subsequently
calculated by plotting the fractional activity versus inhibitor
concentration, fitting the data to the Morrison equation (Fig-
ure 6B), and converting the obtained value to the true Ki by
applying the appropriate Cheng-Prusoff equation (Copeland,
2000, 2005). The mode of inhibition was established using
a method specifically developed for tight-binding inhibitors in
which IC50 values are determined at a fixed enzyme concentra-
tion, but in the presence of increasing concentrations of either
P-Pan (6) or CTP (Figure 6C). A linear increase in IC50 values
with increasing concentration of P-Pan but not CTP indicates
that inhibition is competitive toward P-Pan but noncompetitive
toward CTP (Copeland, 2000, 2005). This observation agrees
with previous studies of the E. faecalis and human PPCS
enzymes that determined an ordered Bi Uni Uni Bi Ping-Pong
kinetic mechanism with CTP binding first, followed by P-Pan
(6) (Yao and Dotson, 2009; Yao et al., 2009). In this manner,
a Ki of 164.3 nM was determined for P-CJ’s inhibition of
EcPPCS.
While EcPPCS is a convenient and well-studied model to use
for characterization of CJ-based inhibition, E. coli is not affectedChemistry & Biology 19,by CJ-15,801 due to the gatekeeping activity of its PanK (Tables
S1 and S2). We therefore performed the same kinetic analysis on
SaCoaBC, which is expected to be the natural target for CJ-
15,801’s observed antistaphylococcal action. A progress curve
analysis similar to that conducted on EcPPCS showed that
SaCoaBC experiences time-dependent inhibition, since the
curves showed a fast initial velocity (vi) phase and a slower
steady-state velocity (vs) phase (Figure 6D). The first order rate
of inactivation constants (kobs) were subsequently determined
and plotted against the inhibitor concentration. The resulting
plot (Figure 6E) showed a linear relationship between kobs and
[I], which points to a one-step inhibition mechanism (Copeland,
2005). However, it is more likely that the true mechanism
consists of two steps, with P-CJ 13 binding first in a reversible
manner, followed by the slow formation of P-CJ-CMP. Such
a mechanism would be kinetically indistinguishable from a
one-step mechanism.
The Ki value for the inhibition of SaCoaBC by P-CJ-CMP can
be determined from the slope and y-intercept of the linear plot
shown in Figure 6E. The Ki value can also be calculated by using
the progress curves to determine the steady-state velocity (vs) at
each inhibitor concentration; a plot of the fractional activity
against inhibitor concentration yields an isotherm curve with
theKi at its midpoint (Figure 6F) (Copeland, 2005). In thismanner,559–571, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 565
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Mode of Action of the Antibiotic CJ-15,801Ki values of 13.0 and 13.5 nM were determined, respectively.
These values is nearly an order of magnitude lower than that
determined for EcPPCS, clearly showing that the nature of the
actual target protein also plays an important role in the extent
of inhibition. Taken together, these data show that P-CJ-CMP
acts as a tight-binding inhibitor of PPCS enzymes.
Analysis of the Mechanistic Basis for the Tight-Binding
Inhibition of P-CJ-CMP
The close structural homology between P-Pan-CMP (14) and
P-CJ-CMP (16), and the fact that both compounds contain reac-
tive acyl phosphate moieties, raises a question regarding the
mechanistic basis for the inhibition by P-CJ-CMP. We consid-
ered three possible explanations: first, inhibition is based on
differences in the electrophilicity of the carbonyl carbon of the
acyl phosphatemoieties of P-Pan-CMP and P-CJ-CMP, respec-
tively; second, inhibition is caused by the two compounds having
different binding modes in the active site, due to the structural
nature of the planar N-acyl vinylogous carbamate functionality
of P-CJ-CMP; and third, inhibition is caused by P-Pan-CMP
and P-CJ-CMP having different effects on any conformational
changes that occur during catalysis through stabilization of the
protein’s quaternary structure. While the significant synthetic
effort that is required to prepare P-Pan-CMP and P-CJ-CMP
precluded a direct experimental comparison of their respective
reactivities, we were able to perform tests to assess whether
the latter two proposed mechanisms contribute to inhibition.
To establish if P-Pan-CMP (14) and P-CJ-CMP (16) have
different binding modes, we used the only available structure
of a PPCS enzyme with its intermediate bound, that of the
EcPPCS Asn210Asp mutant with P-Pan-CMP bound in the
active site (PDB ID: 1U7Z). Thismutant, which accumulates suffi-
cient amounts of the intermediate to have allowed direct confir-
mation of its identity and structure (Kupke, 2004; Stanitzek et al.,
2004), is apparently unable to catalyze the second step of the
PPCS reaction. However, the molecular basis for this catalytic
disability remains speculative since no PPCS structure with
cysteine bound has been determined thus far. Nonetheless,
the mutation clearly results in tightly bound P-Pan-CMP in the
enzyme’s active site.
We constructed a model of the native enzyme by reversing the
Asn210Asp mutation in the crystal structure and used it to dock
P-CJ-CMP (16) in the active site using 150 starting conforma-
tions to ensure sufficient conformational space was sampled
considering the complexity of the molecule. The highest scoring
docked pose of P-CJ-CMP very closely mimics the pose of the
cocrystalized P-Pan-CMP in the crystal structure (Figure 7A),
and facilitates all the same hydrogen bonding interactions while
maintaining a near planar geometry across theN-acyl vinylogous
carbamate moiety (Figure 7B). This suggests that the basis for
inhibition by P-CJ-CMP is not due it having a different binding
mode, or taking on a potentially unreactive conformation.
Members of the ANL superfamily of adenylating enzymes,
such as the adenylation domains of the NRPSs, use a large
domain rotation event to facilitate the catalysis of their two-
step reactions (Gulick, 2009). While it is currently unknown
whether PPCS enzymes, which belong to the ribokinase family,
undergo similar large conformational changes during catalysis,
the determined crystal structures of the E. coli and human566 Chemistry & Biology 19, 559–571, May 25, 2012 ª2012 Elsevierproteins show that they occur as dimers, with the dimer interface
partially occluding the active site (Manoj et al., 2003; Stanitzek
et al., 2004). To evaluate the effect of different ligands on the
enzyme’s overall stability, the melting temperatures (Tm) of
the EcPPCS protein in the presence of its native substrates or
the inhibitor were determined by following the heat-induced
denaturation of these mixtures by circular dichroism (CD). The
results show that the Tm increases from 47.7
C (for the free
enzyme) to 49.7C (for the enzyme bound to CTP) to 54.3C
(for the enzyme bound to P-Pan-CMP, formed in situ from
P-Pan and CTP), highlighting the many stabilizing interactions
the protein has with its native ligands (Figure 7C). Importantly,
the Tm of EcPPCS bound to P-CJ-CMP (formed in situ from
P-CJ and CTP) shows an even larger increase to 57.3C. When
the same experiment was conducted with the bifunctional
SaCoaBC, the protein showed increased stability compared to
EcPPCS (CoaBC proteins exists as higher order oligomers,
usually dodecamers [Manoj et al., 2003]), but only small differ-
ences in the Tm values for the protein in the absence and
presence of its native ligands. However, the Tm showed an
impressive improvement from 65C to 85C for the proteins
bound to P-Pan-CMP and P-CJ-CMP, respectively (Figure 7D).
Taken together, these findings indicate that the binding of the
conformationally more rigid ligand 16 results in an increased
stabilization of the PPCS oligomers and the trapping of the ligand
in the active site. This stabilization, which may be due to interac-
tions between the ligand and residues of the adjacent monomer
(such as Lys289, see Figure 7B) contained in a disordered loop
that partially covers the entrance to the active site (Figure 7E),
is therefore most likely an important contributor to the mecha-
nism of inhibition by P-CJ-CMP.
DISCUSSION
One of the biggest obstacles to elucidation of the CJ-15,801
mode of action is scarcity of the natural product. The original
discoverers shared the bulk of the isolated material with the
authors of a malaria parasite inhibition study (Spry et al., 2008),
but new stocks are unlikely to be obtained in this manner since
the CJ-producing Seimatosporium strain can currently not be
traced due to closure of the laboratory in which it was character-
ized (Y. Sugie, personal communication). New developments in
the synthesis of CJ-15,801 have certainly improved the situation,
but the unique sensitivity of the N-acyl vinylogous carbamic acid
functionality still presents a significant challenge to the synthesis
of this antibiotic.
The original finding that CJ-15,801 is highly selective in its anti-
biotic action, affecting only S. aureus strains among a range of
other Gram-positive bacteria including Streptococcus and
Enterococcus spp. (Sugie et al., 2001), provoked curiosity in
regards to its mechanism of action. Here, we show that the
primary reason for this selectivity is the substrate specificity of
the host organism’s PanK enzyme. Only the PanKII of S. aureus
accepts CJ-15,801 and phosphorylates it, thereby allowing it to
enter the CoA biosynthetic pathway. Interestingly, SaPanKII is
the only known active bacterial representative of a type II PanK;
all other examples occur in eukaryotes. However, an earlier study
showed that CJ-15,801 does not inhibit rat hepatoma cells,
suggesting that typical eukaryotic PanKs do not act asLtd All rights reserved
Figure 7. Structural Basis for the Tight-Binding Inhibition of the CJ-15,801-Derived Inhibitor
(A) Structure of the P-CJ-CMP inhibitor 16 (stick structure with carbon atoms in yellow) modeled and overlaid on that of the P-Pan-CMP intermediate 14 (stick
structure with carbon atoms in blue) bound in the active site of native EcPPCS. The model was created from the crystal structure of EcPPCS Asn210Asp with
cocrystalized P-Pan-CMP 14 bound (PDB: 1U7Z) by reversing the mutation, and docking P-CJ-PMP. The highest scoring pose of P-CJ-CMP closely resembles
that of P-Pan-CMP and similarly facilitates all hydrogen bonding interactions observed for P-Pan-CMP. Only selected residues are shown for clarity.
(B) Schematic view of polar interactions between P-CJ-CMP and EcPPCS. Residues from monomer A are in blue and those from monomer B in green. The key
interaction between Asn210 and the acyl phosphate carbonyl, mediated via a bridging water molecule, is shown in red.
(C) Heat-induced protein melting curves for EcPPCS. The four curves represent from left to right: the free protein (d); protein withMgCTP (7); protein withMgCTP
and P-Pan (2) (-); and protein with MgCTP and P-CJ (13) (---). The curves were determined by following changes in the protein’s secondary structure by
circular dichroism.
(D) Heat-induced protein melting curves for SaCoaBC determined as for EcPPCS in (B).
(E) Structure of the EcPPCS dimer (PDB: 1U7Z) with one monomer shown as a solvent-accessible surface (in cyan) and the other as ribbon structure (in green).
The overlayed P-Pan-CMP and P-CJ-CMP stick structures are shown docked in the active site. Note that residues 291–298, which form part of a loop (shown in
white) that cover the active site, is normally disordered and is absent in all crystal structures of PPCS enzymes (Manoj et al., 2003; Stanitzek et al., 2004).
See also Figure S4.
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Mode of Action of the Antibiotic CJ-15,801gateways to its antibiotic action (Saliba and Kirk, 2005). Such
a conclusion is supported by the results of a structure-activity
relationship study of the inhibition of EcPanKI and the PanKIIs
from Aspergillus nidulans,Mus musculus (mouse), and S. aureus
by the pantothenamides, which showed a clear differentiation
between eukaryotic PanKIIs and SaPanKII, and even between
the eukaryotic PanKIIs themselves (Virga et al., 2006). The varied
selectivity of PanKIIs have clearly not been fully explored, since
P. falciparum (which is also sensitive to inhibition by CJ-15,801)
is also predicted to have a PanKII (Spry et al., 2010).
The evolution of CJ-15,801 as a natural product that specifi-
cally targets the S. aureus CoA biosynthetic pathway may reflect
this organism’s unique redox physiology. Like some other Gram-
positive bacteria, includingBacillus anthracis (Nicely et al., 2007),
S. aureus does not contain glutathione but instead relies on the
sacrificial oxidation of CoA and a specific NADPH- and flavin-Chemistry & Biology 19,dependent CoAdisulfide reductase (CoADR) enzyme tomaintain
its intracellular redox balance (delCardayre and Davies, 1998;
Mallett et al., 2006). This causes S. aureus to maintain high intra-
cellular levels of reduced CoA (Newton et al., 1996), which
imparts an additional unique characteristic to SaPanKII: unlike
other eukaryotic PanKIIs, it is refractory to feedback inhibition
by CoA and its thioesters (Choudhry et al., 2003; Hong et al.,
2006; Leonardi et al., 2005). The combination of S. aureus’s
distinctive reliance on CoA biosynthesis and the unique charac-
teristics of its SaPanKII enzyme have seemingly created an ideal
target for antibacterial action that was eventually exploited
through the production of CJ-15,801.
The interaction between CJ-15,801 and pantothenic acid and
its analogs is complex, and warrants further study (Figures 4A
and 4B). The observation that inhibition by CJ-15,801 is allevi-
ated in the presence of either pantothenic acid or pantetheine559–571, May 25, 2012 ª2012 Elsevier Ltd All rights reserved 567
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Mode of Action of the Antibiotic CJ-15,801is expected in light of its determined mode of action; however, it
is unclear why the inhibition returns when the concentrations
of the vitamin is increased beyond a certain level. It is possible
that the susceptibility to CJ-15,801 under these circumstances
is due to the high concentrations of pantothenic acid stimu-
lating CoA biosynthesis, as this would result in increased
amounts of P-CJ-CMP being formed. The low levels of inhibition
seen in the absence of pantothenic acid in organisms such as
P. aeruginosa that cannot form P-CJ (andwhich therefore should
not experience any inhibition by the mechanism proposed here)
is probably due to similar effects on the regulation of pantothenic
acid biosynthesis and/or utilization. However, such effects are
clearly weak, as they are completely abolished in the presence
of increased concentrations of the vitamin.
The finding that CJ-15,801 and members of the pantothena-
mide class of antibiotics work in a synergistic fashion supports
most studies that have indicated that the pantothenamides
have a target downstream of CoA biosynthesis (Figure 4C)
(Leonardi et al., 2005; Mercer et al., 2009; Thomas and Cronan,
2010; Zhang et al., 2004). Moreover, such a combination can
apparently maintain its inhibitory effects even in the presence
of pantothenic acid (Figure 4D). This indicates that it is possible
to increase the modest antistaphylococcal activity of CJ-15,801
and even counteract the antagonism caused by pantothenic
acid by combining it with other appropriate inhibitors, especially
those that also affect CoA-based metabolism.
The finding that P-CJ-CMP acts as a tight-binding inhibitor of
the PPCS enzyme can be rationalized in light of the findings of
previous studies that have shown that nonhydrolyzable mimics
of acyl nucleotidylate intermediates are often potent (tight-
binding) inhibitors of enzyme activity (Cisar and Tan, 2008; Kim
et al., 2003; Schimmel et al., 1998). In fact, this strategy was
also successfully applied to PPCS in a study in which the phos-
phodiester analog of P-Pan-CMP was shown to be a potent
inhibitor of the PPCS of E. faecalis (Patrone et al., 2009).
However, the finding that P-CJ-CMP does not undergo attack
by cysteine in spite of having an activated acyl phosphatemoiety
remains surprising. Of the three possible mechanisms that were
considered for the inhibition by P-CJ-CMP, the most likely is that
the introduction of the conjugated system in the b-alaninemoiety
reduces the reactivity of the acyl phosphate carbonyl toward
nucleophilic attack. Such a reduced activity could be based on
electronic effects, or be due to the potential tautomerization of
the carbonyl enamine function of the inhibitor to an enol imine.
Such a modification in reactivity has been noted in similar
systems, as in the case of the vinylogous carbamate ester that
forms as a result of the mechanism of action of the b-lactamase
inhibitor clavulanate (and penam sulfones), and which has been
reported to be stable toward hydrolysis (Imtiaz et al., 1993).
However, structural studies have indicated that this stability is
partly due to interactions with active site residues, and that
it can be enhanced by manipulation of these interactions
(Padayatti et al., 2005, 2006). Our model of P-CJ-CMP docked
in the active site of EcPPCS does not show the formation of
any new active site-ligand interactions that are not present
with P-Pan-CMP, suggesting that such factors are not at play
in the inhibition of PPCS by P-CJ-CMP.
Our experiences with the synthetic preparation of CJ-15,801
(Figure 2) indicated that the conjugation provided by the unsatu-568 Chemistry & Biology 19, 559–571, May 25, 2012 ª2012 Elsevierrated b-alanine moiety does deactivate this center. Specifically,
all chemical attempts to hydrolyze the methyl esters 9 and 11 en
route to 1 proved difficult and inefficient, which necessitated
the use of an allyl ester protection strategy that deprotects via
nonhydrolytic mechanisms. However, direct evidence for the
difference in reactivities between P-CJ-CMP and P-Pan-CMP
will have to be obtained through experimentation with model
systems; these studies are currently under way.
Nonetheless, the results of the temperature melting curve
analyses clearly show that P-CJ-CMP also significantly
improves the overall stabilization of PPCS oligomers compared
to the natural intermediate P-Pan-CMP, indicating that the stabi-
lization of certain conformations of the enzyme could also be an
important factor causing inhibition. The finding that the extent of
apparent stabilization is much larger for SaCoaBC than EcPPCS
(which is in agreement with the significantly lower Ki observed in
the case of the former protein) could be due to the increase in
stability being compounded in the bifunctional CoaBC proteins
that usually form dodecamers instead of the dimers formed by
most PPCS enzymes. We conclude that this stabilization
prevents further reaction by cysteine by protecting the poten-
tially reactive P-CJ-CMP intermediate, resulting in its trapping
in the active site and the observed inhibition. This analysis is
supported by the available EcPPCS structures, which show
significant differences in the active site architectures of the
CTP (PDB: 1U7W), P-Pan-CMP (PDB: 1U7Z), and CMP-bound
(PDB: 1U70) forms of the enzyme, indicating that the enzyme
undergoes significant movement during catalysis.
In conclusion, we have demonstrated that the natural product
CJ-15,801 hijacks the CoA biosynthetic pathway, and inhibits its
second enzyme by forming a tight-binding inhibitor in situ within
the active site. This mechanism is highly reminiscent of that of
the sulfonamide antibiotics, which inhibit the biosynthesis of
another vitamin—folic acid—in a similar manner. The mecha-
nism is also complementary to that employed by an adenosine
sulfamate inhibitor of ubiquitin-like protein conjugation path-
ways, which also forms a nonhydrolyzable mimic of its target’s
reaction intermediate in situ (Brownell et al., 2010; Chen et al.,
2011). Taken together, these findings provide important new
insights into inhibitors that target CoA biosynthesis and CoA-
utilizing enzymes. They also highlight an alternative strategy for
inhibitor development—one based on the stabilization of certain
protein conformations—that may also hold significant potential
for drug design efforts targeting other medicinally relevant
synthetase enzymes.
SIGNIFICANCE
The antibiotic CJ-15,801was found to be a selective inhibitor
of CoA biosynthesis inS. aureus due to the unique selectivity
of SaPanK, the first enzyme of the CoA pathway, which
currently is the only known example of an active bacterial
PanKII enzyme. This demonstrates that the diversity of
PanK enzymes can be exploited for selective inhibition or,
as in this case, specific gatekeeping functions. The phos-
pho-CJ-15,801 product that forms as a result of the phos-
phorylation by PanK subsequently acts as a substrate for
PPCS, which transfers a cytidyl group to its carboxylate to
form P-CJ-CMP. Surprisingly, this reaction does not resultLtd All rights reserved
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Mode of Action of the Antibiotic CJ-15,801in the formation of an electrophilically reactive intermediate;
instead P-CJ-CMP acts as a potent tight-binding inhibitor of
the enzyme. The results of temperature-dependent stability
studies indicate that this inhibition is at least partly due to
stabilization of the interactions between the adjacent
monomers in the PPCS dimer, which seemingly prevents
the reaction of cysteine—the second substrate in the PPCS
reaction—with the activated acyl group of P-CJ-CMP. These
findings indicate that the inhibitionof synthetaseenzymesby
nonreactive analogs of their intermediates may have an
alternative mechanistic basis in some cases, which is the
stabilization of certain structural conformations, and that
this should be considered as a potential new strategy for
the inhibition of these enzymes. The findings also reveal
CJ-15,801 as an antimetabolite of a vitamin biosynthetic
pathway, similar to the sulfonamide antibiotics. Finally, we
show that the potency of CJ-15,801 is significantly improved
incombinationwith apantothenamide, aknownCoAantime-
tabolite precursor, confirming that these antimicrobials have
different points of action and establishing the potential of
drug development strategies that are focused on enzymes
involved in CoA biosynthesis and utilization.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for full details of all synthetic
procedures (including characterization data for all compounds), antibacterial
activity assays, procedures for the preparation of proteins, enzyme assays
and accompanying data analyses, and protein melting temperature determi-
nations and analysis.
Synthesis of CJ-15,801 and Its Analogs
The inhibitor and its analogs were prepared by modification of published
procedures (Figure S3) (Nicolaou and Mathison, 2005; Sewell et al., 2011; Villa
et al., 2007).
Inhibition Assays and Analysis
The activity of CJ-15,801 against test strains of S. aureus, Streptococcus
agalactiae, E. coli, P. aeruginosa, and Bacillus subtilis was assessed by MIC
assays performed by microbroth dilution in 96-well microtiter plates and turbi-
dometric analysis at OD600. The effect of pantothenate and its analogs on the
antibiotic activity of CJ-15,801 against S. aureus was assessed in a checker-
board assay to calculate FICI indicative of synergy, additivity, indifference, or
antagonism (Orhan et al., 2005).
PanK Assay and Data Analysis
Pantothenate kinase activity was determined using a continuous spectropho-
tometric assay that coupled the production of ADP to the consumption of
NADH as described previously (Brand and Strauss, 2005; Strauss and Begley,
2002). All enzyme assays were based on decrease of NADH concentration, as
monitored by change in absorbance at 340 nm. An extinction coefficient of
6,220 M1$cm1 was used for NADH. Assays were performed in 96-well
UV transparent plates (Greiner Bio) and monitored for between 10 min and
1 hr at 25C using a Perkin-Elmer HTS 7000 Bio-Assay Reader or a Thermo
Scientific Varioskan Multimode Reader. For EcPanKI and SaPanKII, each
320 ml reaction contained ATP (1.5 mM), MgCl2 (10 mM), KCl (20 mM),
NADH (0.3 mM), phosphoenolpyruvate (0.5 mM), pyruvate kinase (5 units),
and lactate dehydrogenase (5 units) in 50 mM HEPES buffer (pH 7.5). For
PaPanKIII, each 300 ml contained ATP (5.0 mM), MgCl2 (1 mM), NH4Cl
(60 mM), NADH (0.5 mM), phosphoenolpyruvate (2.0 mM), pyruvate kinase
(2 units), and lactate dehydrogenase (2.75 units) in 100 mM HEPES buffer
(pH 7.5). The concentration of pantothenate, CJ-15,801, and other substrate
analogs was varied between 6.25 and 200 mM. Reactions were initiated by
addition of SaPanKII (3 mg), EcPanKI (3.5 mg), or PaPanKIII (5 mg). InitialChemistry & Biology 19,velocities were calculated for each substrate concentration and fitted to the
Michaelis-Menten equation using Prism software (Graphpad) or SigmaPlot
11.0 (Systat software). All measurements were obtained in triplicate.
PPCS Assay and Data Analysis
PPCS assays were performed according to the published procedure (Patrone
et al., 2009; Yao et al., 2009). The PPCS reaction was observed in the forward
reaction via an enzyme-linked assay in which the pyrophosphate that is
released during transfer of CMP from CTP to the substrate is continuously
detected; this is achieved using the commercially available pyrophosphate
reagent from Sigma-Aldrich (Cat. # P7275). Each vial of the pyrophosphate
reagent was resuspended in 4.5 ml of dH2O. The assays were performed on
a Biotek PowerWave microplate spectrophotometer at 37C. All curve-fitting
analyses were performed using SigmaPlot 11.0 (Systat software).
Molecular Modeling
Modeling studies were performed using Accelrys Discovery Studio 3.1 (DS
3.1). The coordinates for EcPPCS Asn210Asp containing P-Pan-CMP as
a cocrystalized ligand were obtained from the Protein Data Bank (PDB code:
1U7Z). The structure was optimized prior to any receptor-ligand calculations
(full details of the receptor preparation are given in the Supplemental Experi-
mental Procedures). Docking of P-CJ-CMPwas accomplished using CDocker
(Wu et al., 2003), launched from within DS 3.1. Deviations from the default
settings included generating 150 starting conformations of the ligands to
adequately sample conformational space and 50 poses were selected for
simulated annealing. The top scoring pose (CDOCKER_Energy) was visually
inspected and found to mimic the binding of the co-crystalized P-Pan-CMP.
To ensure that the optimized water bridging the connection between the
Asn210 amide side chain and the phosphate of P-Pan-CMP was not biasing
the pose found in the docking, the exercise was repeated without this water
molecule, which resulted in a nearly identical pose being found. Similarly,
docking of P-CJ-CMP in the original structure of the EcPPCS Asn210Asp
mutant (1U7Z) again showed that P-CJ-CMP very closely mimics the binding
pose of the P-Pan-CMP molecule cocrystallized in the active site (Figure S4).
Protein Melting Temperature Determinations and Analysis
Protein melting curves were determined by measuring the heat-induced
unfolding of the PPCS proteins by circular dichroism (CD) at 220 nm in
a 0.5 mm cuvette using an Applied Photophysics Chirascan-Plus CD spec-
trometer. Samples contained the PPCS protein (10 mM) and MgCl2 (1 mM) in
50 mM Tris-HCl buffer (pH 7.6) and CTP (150 mM), CTP and P-Pan (150 mM
each), or CTP and P-CJ (150 mM each).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2012.03.013.
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